+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 2Years - 21Years
All Genders
ID04166409

Comparison of Selumetinib Versus Carboplatin and Vincristine for Newly Diagnosed or Untreated Low-Grade Glioma Without BRAFV600E Mutation or Neurofibromatosis Type 1

Led by National Cancer Institute (NCI) · Updated on 2026-10-29

170

Participants Needed

132

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This trial evaluates treatments for children and young adults aged 2 to 21 with newly diagnosed or untreated low-grade glioma LGG that does not have a BRAFV600E mutation or systemic neurofibromatosis type 1. The study aims to compare the effects of selumetinib, an oral drug that blocks enzymes needed for cell growth, with the standard chemotherapy regimen of carboplatin and vincristine. The main goal is to determine if selumetinib is as effective as the standard treatment in preventing disease events and to see if it improves quality of life. Participants are randomly assigned to one of two treatment groups. One group receives vincristine and carboplatin intravenously during an induction phase followed by maintenance cycles every 42 days for up to 8 cycles. The other group takes selumetinib orally twice daily in 28-day cycles for up to 27 cycles. Both groups undergo regular blood collection and MRI scans throughout treatment. The selumetinib group also has heart function evaluated by echocardiography at the start. During the study, participants will have assessments including visual acuity tests, motor function evaluations, quality of life and cognitive function questionnaires. Follow-up visits occur every 3 months for the first year, then every 6 months for years 2 and 3, and annually thereafter up to 10 years. The primary outcome measured is event-free survival over this period. The study also collects tumor and blood samples to explore genetic factors related to treatment response.

CONDITIONS

Brief Title

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here